| | The long-term consequences of the HPV vaccine are unknown as there have not been any long-term studies. Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine. Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine. | | The long-term consequences of the HPV vaccine are unknown as there have not been any long-term studies. Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine. Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine. |
| − | A study published February 28, 2007 in the Journal of the American Medical Association (JAMA) <ref>JAMA 297(8):813-819, February 28, 2007</ref> disclosed that about 3% of women are infected in their lifetime by the particular types of HPV (Types 6, 11, 16, 18) targeted by the vaccine. <!-- ''this assertion is dubious; the latest figures from CDC [http://www.cdc.gov/std/stats/trends2006.htm here] say that chlamydia is the most common; Time may be applying different critera, which should be stated.'' ''Time'' magazine calls HPV "the most common sexually transmitted infection".<ref>[http://www.time.com/time/nation/article/0,8599,1206813,00.html Defusing the War Over the "Promiscuity" Vaccine]</ref>--> | + | A study published February 28, 2007 in the Journal of the American Medical Association (JAMA) <ref>JAMA 297(8):813-819, February 28, 2007</ref> disclosed that about 3% of women are infected in their lifetime by the particular types of HPV (Types 6, 11, 16, 18) targeted by the vaccine.<ref>"HPV vaccine types 6 and 11 (low-risk types) and 16 and 18 (high-risk types) were detected in 3.4% of female participants." [http://jama.ama-assn.org/cgi/content/abstract/297/8/813]</ref> |
| | Merck manufactures the HPV vaccine ("Gardasil") and sells it for $360 ($120 per shot in a three-shot series). Its package insert explains the limitations of the vaccine and describes its testing for safety and efficacy.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> | | Merck manufactures the HPV vaccine ("Gardasil") and sells it for $360 ($120 per shot in a three-shot series). Its package insert explains the limitations of the vaccine and describes its testing for safety and efficacy.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> |